Immune Portrayal of a New Therapy Targeting Microbiota in an Animal Model of Psoriasis
-
Published:2023-10-30
Issue:11
Volume:13
Page:1556
-
ISSN:2075-4426
-
Container-title:Journal of Personalized Medicine
-
language:en
-
Short-container-title:JPM
Author:
Surcel Mihaela1, Constantin Carolina12, Munteanu Adriana Narcisa13, Costea Diana Antonia13, Isvoranu Gheorghița4, Codrici Elena5, Popescu Ionela Daniela5, Tănase Cristiana6, Ibram Alef7, Neagu Monica123ORCID
Affiliation:
1. Immunology Department, Victor Babes National Institute of Pathology, Splaiul Independentei 99-101, 050096 Bucharest, Romania 2. Department of Pathology, Colentina University Hospital, Șos. Ștefan cel Mare 19-21, 020125 Bucharest, Romania 3. Doctoral School of Biology, Faculty of Biology, University of Bucharest, Splaiul Independentei 91-95, 050095 Bucharest, Romania 4. Animal Husbandry, Victor Babes National Institute of Pathology, Splaiul Independentei 99-101, 050096 Bucharest, Romania 5. Biochemistry-Proteomics Department, Victor Babes National Institute of Pathology, Splaiul Independentei 99-101, 050096 Bucharest, Romania 6. Faculty of Medicine, Titu Maiorescu University, Calea Văcăreşti 189, 031593 Bucharest, Romania 7. Research Laboratory, Romvac Company SA, Şos. Centurii 7, 077190 Voluntari, Romania
Abstract
Background: Despite all the available treatments, psoriasis remains incurable; therefore, finding personalized therapies is a continuous challenge. Psoriasis is linked to a gut microbiota imbalance, highlighting the importance of the gut–skin axis and its inflammatory mediators. Restoring this imbalance can open new perspectives in psoriasis therapy. We investigated the effect of purified IgY raised against pathological human bacteria antibiotic-resistant in induced murine psoriatic dermatitis (PSO). Methods: To evaluate the immune portrayal in an imiquimod experimental model, before and after IgY treatment, xMAP array and flow cytometry were used. Results: There were significant changes in IL-1α,β, IL-5, IL-6, IL-9, IL-10, IL-12 (p70), IL-13, IL-15, IL-17a, IFN-γ, TNF-α, IP-10/CXCL10, MCP-1/CCL2, MIP-1α/CCL3, MIP-1β/CCL4, MIG/CXCL9, and KC/CXCL1 serum levels. T (CD3ε+), B (CD19+) and NK (NK1.1+) cells were also quantified. In our model, TNF-α, IL-6, and IL-1β cytokines and CXCL1 chemokine have extremely high circulatory levels in the PSO group. Upon experimental therapy, the cytokine serum values were not different between IgY-treated groups and spontaneously remitted PSO. Conclusions: Using the murine model of psoriatic dermatitis, we show that the orally purified IgY treatment can lead to an improvement in skin lesion healing along with the normalization of cellular and humoral immune parameters.
Funder
Ministry of Research, Innovation and Digitization, CCCDI-UEFISCDI (PNCDI III); Core Program, implemented with the support of NASR; Competitiveness Operational Program (COP);
Subject
Medicine (miscellaneous)
Reference77 articles.
1. Tashiro, T., and Sawada, Y. (2022). Psoriasis and Systemic Inflammatory Disorders. Int. J. Mol. Sci., 23. 2. Jansen, J.E., Aschenbrenner, D., Uhlig, H.H., Coles, M.C., and Gaffney, E.A. (2022). A method for the inference of cytokine interaction networks. PLoS Comput. Biol., 18. 3. Multiorgan-on-a-chip for realization of gut-skin axis;Lee;Biotechnol. Bioeng.,2022 4. Ion, A., Dorobanțu, A.M., Popa, L.G., Mihai, M.M., and Orzan, O.A. (2022). Risks of Biologic Therapy and the Importance of Multidisciplinary Approach for an Accurate Management of Patients with Moderate-Severe Psoriasis and Concomitant Diseases. Biology, 11. 5. Probiotics Supplementation Improves Quality of Life, Clinical Symptoms, and Inflammatory Status in Patients with Psoriasis;Moludi;J. Drugs Dermatol.,2022
|
|